JPS6036966A - Latex reagent for measuring rheumatic factor - Google Patents

Latex reagent for measuring rheumatic factor

Info

Publication number
JPS6036966A
JPS6036966A JP14435383A JP14435383A JPS6036966A JP S6036966 A JPS6036966 A JP S6036966A JP 14435383 A JP14435383 A JP 14435383A JP 14435383 A JP14435383 A JP 14435383A JP S6036966 A JPS6036966 A JP S6036966A
Authority
JP
Japan
Prior art keywords
antigen
latex
latex particles
antibody
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP14435383A
Other languages
Japanese (ja)
Inventor
Susumu Oshima
進 大島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiken Chemical Co Ltd
Original Assignee
Eiken Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiken Chemical Co Ltd filed Critical Eiken Chemical Co Ltd
Priority to JP14435383A priority Critical patent/JPS6036966A/en
Publication of JPS6036966A publication Critical patent/JPS6036966A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PURPOSE:To obtain high specificity and sensitivity by binding chemically or adsorbing physically an antigen to latex particles having a specific grain size and removing the excess amt. of the agtigen then bringing the corresponding antiserum or refined antibody into reaction therewith. CONSTITUTION:Latex is synthetic polymer latex particles of polystyrene, polybutadiene or polystyrene, etc. having a functional group on the surface and the surface thereof may be treated with a nonionic surfactant, etc. The grain size of the latex particles is 0.01-10mu, more preferably 0.1-1.0mu and has preferably a narrow width of the grain size distribution to improve the reproducibility of the result of measurement. The conceivable antigen to be bound chemically or adsorbed physically to the latex particles is the antigen originating in animals such as guinea pig, rabbit, goat, etc. and the antigen stable to heat, acids and alkalis is more preferable as far as said material is recognizable as the antigen. The antibody to be made correspondent to the antigen adsorbed to the latex particles is obtd. from animals such as guinea pig, rabbit, goat, etc. which can produce the antibody.

Description

【発明の詳細な説明】 本発明はりウマチ因子(リウマトイドファクター:RF
と略称する)測定用ラテックス試薬に関するものである
DETAILED DESCRIPTION OF THE INVENTION The present invention provides rheumatoid factor (RF)
This relates to latex reagents for measurement (abbreviated as ).

さらに詳しくは平均粒径0.01〜10Pのラテックス
粒子に化学的結合あるいは物理的吸着によシ抗原を担持
せしめた後)該抗原に対応する抗体を免疫学的反応によ
シ感作せしめたことを特徴とするRF測定用ラテックス
試薬に関するものである。
More specifically, latex particles with an average particle size of 0.01 to 10P are loaded with an antigen by chemical bonding or physical adsorption, and then an antibody corresponding to the antigen is sensitized by an immunological reaction. The present invention relates to a latex reagent for RF measurement characterized by the following.

RFは慢性関節リウマチ(リウマトイドアースライテイ
ス:RA)患者の血清中に出現する物質である。これは
自己および同種あるいは異種のγ−グロブリンと特異的
な親和性をも一−Cいるので自己抗体の一つであろうと
想像されている。
RF is a substance that appears in the serum of patients with rheumatoid arthritis (RA). This antibody is thought to be one of the autoantibodies since it has a specific affinity for self and homologous or foreign γ-globulin.

RF検出に用いられる血清学的検査法を大別すると11
)ウサギ免疫抗体あるいはウサギ変性γ−グロブリンを
感作した血球凝集反応と蔦2)血精学的に不活性なラテ
ックスにヒトγ−グロブリンを吸着させたラテックス凝
集反応とに分けられ゛る。
There are 11 major classifications of serological testing methods used for RF detection.
2) Latex agglutination reaction, in which human γ-globulin is adsorbed to hematologically inert latex.

一般に1)の感作血球凝集反応は2)の感作ラテツクス
凝集反応に比して感度は劣るが船具1隻において優れて
いる。す々わちラテックス凝集反応は操作が簡単で鋭敏
度が高いのでスクリーニングテストとして広く用いられ
るがRA−=以外でもかなシ多くの疾患またとえば肝疾
患為結核1らい1梅毒Aウイルス性疾患為亜急性細菌性
心内膜炎1ザルコイド−ジス1膠原病などで陽性を示す
ので1これらの疾患との鑑別診断の場合には)感作血球
凝集反応によらなければ、なら々い。
Generally, the sensitivity of 1) sensitized hemagglutination reaction is inferior to that of 2) sensitized latex agglutination reaction, but it is superior in one ship equipment. The latex agglutination reaction is easy to operate and has high sensitivity, so it is widely used as a screening test, but it is also used for many diseases other than RA-=, such as tuberculosis for liver disease, leprosy, syphilis A virus disease, etc. Since the test results are positive for acute bacterial endocarditis, sarcoid-disease, collagen disease, etc., the differential diagnosis for these diseases must be based on the sensitized hemagglutination reaction.

感作血球凝集反応にはヒツジ赤血訝と対応する抗ヒツジ
赤血球ウサギ抗体を用いたRose反応とHe’ 11
 e r反応が1またホルマリン・タンニン酸処理した
ヒツジ赤血球に精製ウサギ変性・γ−グロブリンを吸着
した反応がある。これらは被検血清中のヒツジ赤血球に
対する正常異種凝集素や異好抗体による影響を除くため
に11)未感作ヒツジ赤血球を対照において測定する方
法(RoSe法’) N 2)6らかじめヒツジ赤血球
で吸収してから測定する方法(Heller法))3)
ヒツジ赤血球の代用として九ヒツ、ジおよび牛の赤血球
膜溶解成分を含有する緩衝液で吸収する方法がある。
For the sensitization hemagglutination reaction, a Rose reaction using sheep red blood cells and a corresponding anti-sheep red blood cell rabbit antibody and He' 11 were used.
There is also a reaction in which purified rabbit denatured γ-globulin is adsorbed to formalin/tannic acid-treated sheep red blood cells. In order to eliminate the influence of normal xenoagglutinin and heterophilic antibodies on sheep red blood cells in the test serum, 11) A method of measuring unsensitized sheep red blood cells as a control (RoSe method') N2) 6. Method of measuring after absorption by red blood cells (Heller method)) 3)
As a substitute for sheep red blood cells, there is a method of absorbing with a buffer solution containing membrane-dissolving components of sheep, horse and cow red blood cells.

日常の臨床検査ではl)および2)の操作は煩雑である
ため)3)の方法が繁用されている。
In daily clinical tests, method 3) is frequently used because the operations in 1) and 2) are complicated.

しかし1いずれの方法でもRFに被検血清によシ吸収が
不完全なことがあシRFに非特異的な吸収が1れに見ら
れる。
However, in either method, absorption of RF by the test serum may be incomplete, and non-specific absorption of RF may be observed.

本発明者は上記の従来法の欠点のないRFIll11定
法を得るために鋭意研究の結果)特異性および感度が高
くA操作が簡単な新規RF測定用試薬を見い出した。す
なわち)血清学的に不活性な平均粒径0.01〜10P
のラテソク/J、粒7に1壕ず抗原を化学的結合もしく
は物理的吸着させ1残存する過剰量の抗原を遠心分離な
どで除去した後1対応する抗血清あるいは精製抗体を反
応させRF反応因子を結合させることを特徴とするRF
測定用ラテックス試薬を発明した、本発明の目的は)血
清学的に不活性なラテックス粒子にRose法およびH
e1ler法と同様、1ウサギ免疫抗体を抗原抗体反応
を応用して吸収せしめることを特徴としN RFの測定
に際しヒツジ赤血球を担体とした時のような吸収操作は
必要とせず1高い特異性と感度を示すRF測定用ラテッ
クス試薬を提供することにある。
The present inventor conducted extensive research in order to obtain an RF Ill11 standard method that does not have the drawbacks of the above-mentioned conventional methods, and as a result found a new RF measurement reagent that has high specificity and sensitivity and is easy to operate. i.e.) serologically inactive average particle size 0.01-10P
LaTesoku/J, chemically bind or physically adsorb the antigen to each particle 7, remove the remaining excess antigen by centrifugation, etc. 1 react with the corresponding antiserum or purified antibody to form an RF reaction factor. RF characterized by combining
The object of the present invention is to invent a latex reagent for measurement.) The Rose method and H
Similar to the e1ler method, it is characterized by absorbing rabbit immunized antibodies by applying an antigen-antibody reaction, and does not require the absorption procedure when using sheep red blood cells as a carrier when measuring NRF, resulting in high specificity and sensitivity. An object of the present invention is to provide a latex reagent for RF measurement that exhibits the following properties.

次に本発明の詳細な説明する。Next, the present invention will be explained in detail.

本発明に用いられるラテックスはポリスチレン九ポリブ
タジェン)あるいは表面に官能基を有するボリスチしノ
ン等の合成高分子ラテックス粒子で表面を非イオン界面
活性剤等で処理したものであってもよい。ラテックス粒
子の粒径は0・01〜107xであシ1好ましくは0.
1〜1.opでちるが測定結果の再現性を良くするため
に1粒径分布の幅が狭いものが望ましい。使用されるラ
テックス粒子の比重は0.9〜1.4である。
The latex used in the present invention may be synthetic polymer latex particles such as polystyrene (9-polybutadiene) or boristhinone having a functional group on the surface, the surface of which has been treated with a nonionic surfactant or the like. The particle size of the latex particles is 0.01 to 107x, preferably 0.01x.
1-1. In order to improve the reproducibility of measurement results, it is desirable that the width of the particle size distribution is narrow. The specific gravity of the latex particles used is between 0.9 and 1.4.

ラテックス粒子へ化学的結合あるいは物理的吸着せしめ
る抗原としてはモルモット)ウサギ1ヤギ等の動物由来
のものが考えられ1抗原として認識可能な物質であれば
熱や酸・アルカリに安定なものがよシ望ましい。
Antigens that can be chemically bonded or physically adsorbed to latex particles include those derived from animals such as guinea pigs, rabbits, and goats.1If the antigen can be recognized, it is best to use one that is stable against heat, acids, and alkalis. desirable.

ラテックス粒子へ吸着せしめた抗原に対応する抗体はモ
ルモット、ウサギ−ヤギ等の抗体産生可能な動物から得
られる。Rose法やHe1ler法ではウサギ免疫抗
体が使用されているがRF反応因子としては限定される
ものではない。
Antibodies corresponding to antigens adsorbed to latex particles can be obtained from animals capable of producing antibodies, such as guinea pigs, rabbits, and goats. Although a rabbit immune antibody is used in the Rose method and the Heler method, the RF reaction factor is not limited thereto.

壕だ免疫して得られた抗体は抗血清のままでもよいがA
さらに硫安分画法−DEAEイオン交換クロマトグラフ
4−法Aゲルろ過法為エタノール分画法1アフィニティ
ークロマト法等で精製されたr−グロブリン分画でもよ
い。
Antibodies obtained by trench immunization can be left as antiserum, but A.
Furthermore, an r-globulin fraction purified by ammonium sulfate fractionation method - DEAE ion exchange chromatography method 4 - Method A gel filtration method, ethanol fractionation method 1 affinity chromatography method, etc. may also be used.

ラテックス粒子に抗原を相持させるにはカルボキシル化
ポリスチレンにカルボジイミド等のカップリング試薬で
化学的に結合させるか1アミノ化ポリスチレンにグルク
リックアルデヒド等の°カップリンク試薬で化学的に結
合させるか為ポリスチレンラテックスにpH5〜10好
ましくはpH6,5〜8の緩衝液中で4〜40℃で30
分〜24時間物理的に吸着させる方法がある。緩衝液と
しては九例えばリン酸緩衝食塩水Aグリシン緩衝食塩水
を用いる。反応終了後は中性伺近の緩衝液で遠心分離す
るかAろ過することによυ数回洗浄する。次に抗ノ」;
(を結合せしめたラテックス粒子に抗体を担持させるに
は抗原に対応する抗血清あるいは精製抗体を中性伺近の
緩衝液で4〜40℃で30分〜241141間抗原抗体
反応で免疫学的に結合させる。反応終了後は中+r:伺
近の緩衝液で遠心分離するか1ろ過することにより数回
洗浄し1最後に牛アルブミン(BSA )やザソカロー
ス等の安定化剤およびアジ化ナトリウム等の防腐剤を含
有する中性伺近の緩衝液に感作ラテツクス粒子を懸濁し
僅存する。
To make antigens compatible with latex particles, chemically bond them to carboxylated polystyrene using a coupling reagent such as carbodiimide, or chemically bond them to 1-aminated polystyrene using a coupling reagent such as glyclic aldehyde.Polystyrene latex to 30°C at 4-40°C in a buffer of pH 5-10, preferably pH 6,5-8.
There is a method of physically adsorbing the substance for minutes to 24 hours. As the buffer solution, for example, phosphate buffered saline and glycine buffered saline are used. After the reaction is complete, wash several times with a neutral buffer solution by centrifugation or A-filtration. Next is anti-no”;
(To carry antibodies on the bound latex particles, apply an antiserum or purified antibody corresponding to the antigen in a neutral buffer solution at 4 to 40°C for 30 minutes to 241141 using an antigen-antibody reaction. After the reaction is complete, wash several times by centrifugation or filtration with a nearby buffer solution, and finally add stabilizers such as bovine albumin (BSA) or zasocalose and sodium azide. The sensitized latex particles are suspended in a neutral buffer containing a preservative.

これらの感作ラテツクスは1年以上安定である。このよ
うにして得られた感作ラテツクスを用いてマイクロクイ
クー法およびスライド凝集法により血清中のRFを容易
に測定することができる。マイクロタイクー法はマイク
ロトレーに一定量の中性伺近の稀釈液を分注しへ次に第
一大目に血清一定量を加え\ダイリュー一ターで順次稀
釈する。他方)参考陽性血清な用いて同様に稀釈系例を
作製する。これに感作ラテツクスを一定量づつ加えて均
一にし)一定萌間放(1′1した後1凝集の終点をみて
参考賜(’l +m (♂IからRFの凝集価をめるこ
とができる。
These sensitized latexes are stable for more than one year. Using the sensitized latex thus obtained, RF in serum can be easily measured by the microcuicou method and the slide agglutination method. In the microtyke method, a certain amount of a neutral diluent is dispensed into a microtray, then a certain amount of serum is added to the first container, and the solution is sequentially diluted with a diluter. On the other hand) Create a dilution system in the same way using the reference positive serum. Add a certain amount of sensitizing latex to the mixture to make it uniform, and after a certain amount of sensitization release (1'1), check the end point of 1 agglutination and calculate the agglutination value ('l + m). .

またスライド凝集法はスライドガラス上に任意に稀釈し
た被検液を一定量滴下し1別に参考陽性血清も一定量滴
下した後入各々に感作ラテツクスを一定量滴下しAゆる
やかに攪拌する。
In addition, in the slide agglutination method, a certain amount of an arbitrarily diluted test solution is dropped onto a slide glass, a certain amount of a reference positive serum is also added separately, and then a certain amount of sensitizing latex is added dropwise to each slide and stirred gently.

生じた凝集像を判定することにより数分以内にRFの凝
集価を測定することができる。
By determining the resulting agglutination image, the RF agglutination titer can be determined within a few minutes.

本発明のRF filll定用ラテックス試薬はRF反
応因子をラテックス粒子に結合せしめる方法として1精
製した変性γ−グロブリンを化学的結合あるいは物理的
吸着せしめたものでなく1あらかじめ抗原を化学的ある
いは物理的にラテックスに吸着させ)次にその抗原に対
応する抗体すなわちRF’反応因子を抗原抗体反応で免
疫学的に有意義に結合させることを4’!j’ C9と
しておりRose法やHe1ler法と免疫抗体を結合
せしめる点は同様であるがλ血清学的に不活性寿ラテッ
クス粒子を担体として使用しているので)赤正常異種凝
集素や異好抗体による影響がないので1それらを未感作
血球等で吸収防去する操作が必要なく)、 RFとの反
応以夕1に非特異反応が起らない点優れている。さらに
ラテックス粒子な担体として抗原抗体反応を応用し)R
F′反応因子を感作するRF測定用ラテックス試薬の前
例はなく1全く新規なもので必シ1操作の簡便さ1感度
1特異度に優れている。
The RF filling latex reagent of the present invention is a method for binding an RF reaction factor to latex particles.1 It is not a product in which purified denatured γ-globulin is chemically or physically adsorbed. 4'! Next, the antibody corresponding to the antigen, that is, the RF' reaction factor, is bound in an immunologically meaningful manner by an antigen-antibody reaction. j' C9, and is similar in that it binds immune antibodies to the Rose method and Heler method, but since it uses λ serologically inactive Kotobuki latex particles as a carrier), it can be used for red normal xenoagglutinins and heterophilic antibodies. It is advantageous in that there is no need to absorb or remove them with unsensitized blood cells, etc., and no non-specific reactions occur after the reaction with RF. Furthermore, by applying antigen-antibody reaction as a latex particle carrier)
There is no precedent for a latex reagent for RF measurement that sensitizes the F' reaction factor, and it is completely new and has excellent features such as ease of operation, sensitivity, and specificity.

次に本発明を実施例によって)さらに詳細に説明するが
1本発明はその要旨を起えない1沢シ以下の実施例によ
って限定されるものでは力い実施例1.抗生アルブミン
(BSA)抗体の調製市販されている結晶牝牛アルブミ
ン(アーマ−・パーマセテイカル社製)を1ml当92
■になるように生理食塩液に溶かしへ等量のコンエマル
ジョンとしだ後)ウサギを用い)それぞれの四肢の足壓
に皮下注射し1さらに2週間毎に同一組成のエマルジョ
ンで背部皮下に追加免疫する。2箇月後1ウサギの耳部
動脈よj950m1採血し常法に従って遠心分離しλ抗
血清約20m1を得た。
Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited to the following Examples, which do not give rise to the gist of the present invention. Preparation of antibiotic albumin (BSA) antibodies
After diluting an equal amount of con-emulsion into a physiological saline solution, inject it subcutaneously into the foot pad of each limb using a rabbit. do. Two months later, 950 ml of blood was collected from the ear artery of one rabbit and centrifuged in a conventional manner to obtain about 20 ml of λ antiserum.

得られた抗血清は抗原と1オクテロニー法1免疫電気泳
動法λ交互免疫電気泳動法によって一本の沈降線を形成
することがらA単一抗体であることを確認した。
The obtained antiserum was confirmed to be a single antibody A because it formed a single sedimentation line with the antigen by one octellony method, one immunoelectrophoresis method, and one lambda alternating immunoelectrophoresis method.

実施例2.牛アルブミン感作ラテックスの調製ラテック
ス(武田薬品工業株式会社製: 5DL59、比重1.
14、粒径0.8P)をλその粒子濃度が0.5%にな
るように0.1M塩化アンモニウム是衡食塩液pH8,
2で稀釈した液にラテックスト■a、9100Pgの結
晶化牛アルブミンを含む0・IM塩塩化アンモニウム緩
衝塩塩液等量加え為37℃)1時間反応させた後1遠心
分離して未吸着の結晶化牛アルブミンを洗浄除去した後
Aラテン22粒子を0.1M塩塩化アンモニウム緩衝塩
塩液0.596になるように懸濁して)牛アルブミン感
作ラテックスを得る。
Example 2. Preparation of bovine albumin sensitized latex Latex (manufactured by Takeda Pharmaceutical Co., Ltd.: 5DL59, specific gravity 1.
14. Particle size: 0.8P) in 0.1M ammonium chloride balanced saline solution, pH 8, so that the particle concentration becomes 0.5%.
To the solution diluted with 2, add Latex A and an equal volume of 0.IM ammonium chloride buffer salt solution containing 9100 Pg of crystallized bovine albumin (at 37°C). After reacting for 1 hour, centrifuge once to remove unadsorbed After washing and removing crystallized bovine albumin, A Latin 22 particles were suspended in a 0.1M ammonium chloride buffered salt solution to obtain a bovine albumin sensitized latex.

実施例3・ 牛アルブミン感作ラテックスへの抗生アル
ブミン抗体の感作 牛アルブミン感作ラテックスへ抗生アルブミンウサギ血
清を25Pi、加え混和後、 37℃11時間反応させ
)反応終了後遠心分離し)O,’1M塩化アンモニウム
緩衝食塩液で洗浄した後入最終濃度が0.596となる
ように牛アルブミンおよび1%となるようにサッカロー
スを安定剤として加え)ラテックス濃度が0.25%に
なるように塩化アンモニウム緩衝食塩液で懸濁し)ウサ
ギ抗体感作ラテックスすなわち、RF測定用ラテックス
試薬を得る。
Example 3 Sensitization of antibiotic albumin antibodies to bovine albumin-sensitized latex Antibiotic albumin rabbit serum was added to bovine albumin-sensitized latex at 25 Pi, mixed, and reacted for 11 hours at 37°C. After the reaction was completed, centrifuged) 'After washing with 1M ammonium chloride buffered saline, add bovine albumin to a final concentration of 0.596 and saccharose to a final concentration of 1% as a stabilizer) to a latex concentration of 0.25%. A rabbit antibody-sensitized latex (suspended in ammonium buffered saline), that is, a latex reagent for RF measurement is obtained.

実施例4.RFの測定 U字型マイクロプレートの各穴に稀釈液を0゜025m
1づつ分注し、第1大目に血清0.025m1を加えグ
イリュータ−で順次稀釈する。
Example 4. Measurement of RF Add dilution solution to each hole of U-shaped microplate at 0°025m.
Dispense 1 portion at a time, add 0.025 ml of serum to the first portion, and dilute sequentially with a Gailutor.

次いで各穴に1実施例3.で得たRF測定用ラテックス
試薬を0.025+nlづつ分注し)充分に混和して室
温に12時間以上放置して凝集の終点をみる。反応が生
じている場合には)管底全面にラテックスが分散してお
シ1反応が生じていない場合にはA穴の中心にラテック
スが集っていることから1容易に凝集の終点が判断でき
る。
Then apply one Example 3 to each hole. Dispense 0.025+nl of the latex reagent for RF measurement obtained in step 1), mix thoroughly, and leave at room temperature for 12 hours or more to check the end point of aggregation. If a reaction is occurring, the latex will be dispersed all over the bottom of the tube.If a reaction is not occurring, the latex will be concentrated in the center of hole A, so the end point of aggregation can be easily determined. can.

上記の方法に従って典型的な慢性リウマチ患者の血清1
0例と正常人の血i 10例について測定した結果を第
−表に示す。あわせて同一血清での市販RAHAテスト
(A社マイ久ロタイタも示す。
Typical chronic rheumatism patient serum 1 according to the above method
Table 1 shows the results of measurements for 0 cases and 10 cases of normal human blood. Also shown is a commercially available RAHA test (Mykuro Tita, manufactured by A) using the same serum.

以下余白Margin below

Claims (1)

【特許請求の範囲】[Claims] 平均粒径0.01〜10Pのラテックス粒子に\化学的
結合あるいは物理的吸X1によシ抗原を担持せしめた後
1さらに対応する抗体を免疫学的に感作せしめたことを
特徴とするりウマチ因子測定用ラテックス試薬
It is characterized in that latex particles with an average particle size of 0.01 to 10P are loaded with a foreign antigen by chemical bonding or physical adsorption, and then immunologically sensitized with the corresponding antibody. Latex reagent for equine factor measurement
JP14435383A 1983-08-09 1983-08-09 Latex reagent for measuring rheumatic factor Pending JPS6036966A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14435383A JPS6036966A (en) 1983-08-09 1983-08-09 Latex reagent for measuring rheumatic factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14435383A JPS6036966A (en) 1983-08-09 1983-08-09 Latex reagent for measuring rheumatic factor

Publications (1)

Publication Number Publication Date
JPS6036966A true JPS6036966A (en) 1985-02-26

Family

ID=15360128

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14435383A Pending JPS6036966A (en) 1983-08-09 1983-08-09 Latex reagent for measuring rheumatic factor

Country Status (1)

Country Link
JP (1) JPS6036966A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161716A (en) * 2010-12-30 2011-08-24 北京九强生物技术股份有限公司 Method and reagent for latex sensitization

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102161716A (en) * 2010-12-30 2011-08-24 北京九强生物技术股份有限公司 Method and reagent for latex sensitization

Similar Documents

Publication Publication Date Title
JPS6314783B2 (en)
JPH0765998B2 (en) Assay method and assay reagent for specifically binding substances
JPH04350559A (en) Measuring method for specific antibody
JPS58165055A (en) Method of immunologically coagulating latex
JP2638137B2 (en) Apolipoprotein B diagnostic reagent and assay
JPH0239746B2 (en)
GB2030294A (en) Composition for determination of human beta 2-microglobulin, process for its preparation and its use
JP6890444B2 (en) Antigen measurement method, antigen measurement reagent, and measurement kit using antibody-supported insoluble carrier particles immobilized on different loading methods.
JPH0467150B2 (en)
EP0485377B1 (en) Solid phase immuno-assay with labelled conjugate
US5466611A (en) Method for the determination of antigens or antibodies in the presence of an immune complex
JPS6036966A (en) Latex reagent for measuring rheumatic factor
JPS6215464A (en) Non-specific reaction absorbent for reverse passive agglutination reaction
JP2001337092A (en) Immunological measuring method and reagent for measurement
JPS6091264A (en) Immunological measurement of fibrionectin
JPH0448265A (en) Immunoassay
JP7436838B2 (en) Method for measuring hemoglobin A1c using antibody-dendrimer complex
JPH08327629A (en) Pretreatment of specimen
JP3220545B2 (en) Rheumatoid factor determination method and reagent for performing the method
JPH04329357A (en) Immunological measuring method
JP3598701B2 (en) Immunochemical assay using an insoluble carrier
JPS60257363A (en) Measuring method of fdp
JP2704760B2 (en) Agglutinating antibody
JPH0394161A (en) Latex reagent
JPH0230665B2 (en) SHINKINAKOGENTEIRYOHO